Hajek, R. Et Al. 2020. A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. EUROPEAN JOURNAL OF HAEMATOLOGY , vol.104, no.5 , 435-442.

Hajek, R., Pour, L., ÖZCAN, M., Sanchez, J. M., Sanz, R. G., Anagnostopoulos, A., ... Oriol, A.(2020). A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. EUROPEAN JOURNAL OF HAEMATOLOGY , vol.104, no.5, 435-442.

Hajek, Roman Et Al. "A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma," EUROPEAN JOURNAL OF HAEMATOLOGY , vol.104, no.5, 435-442, 2020

Hajek, Roman Et Al. "A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma." EUROPEAN JOURNAL OF HAEMATOLOGY , vol.104, no.5, pp.435-442, 2020

Hajek, R. Et Al. (2020) . "A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma." EUROPEAN JOURNAL OF HAEMATOLOGY , vol.104, no.5, pp.435-442.

@article{article, author={Roman Hajek Et Al. }, title={A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma}, journal={EUROPEAN JOURNAL OF HAEMATOLOGY}, year=2020, pages={435-442} }